These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31985584)

  • 21. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
    Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
    Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonate drug holidays--when, why and for how long?
    Anagnostis P; Stevenson JC
    Climacteric; 2015; 18 Suppl 2():32-8. PubMed ID: 26507608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonate holidays.
    Reid IR
    Drug Ther Bull; 2021 Mar; 59(3):35-36. PubMed ID: 33627350
    [No Abstract]   [Full Text] [Related]  

  • 25. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
    Adler RA; El-Hajj Fuleihan G; Bauer DC; Camacho PM; Clarke BL; Clines GA; Compston JE; Drake MT; Edwards BJ; Favus MJ; Greenspan SL; McKinney R; Pignolo RJ; Sellmeyer DE
    J Bone Miner Res; 2016 Jan; 31(1):16-35. PubMed ID: 26350171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
    Sánchez A; Blanco R
    Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bisphosphonates treatment in patients with osteoporosis].
    Rizzoli R
    Ther Umsch; 2012 Mar; 69(3):173-81. PubMed ID: 22403110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study.
    Adams AL; Adams JL; Raebel MA; Tang BT; Kuntz JL; Vijayadeva V; McGlynn EA; Gozansky WS
    J Bone Miner Res; 2018 Jul; 33(7):1252-1259. PubMed ID: 29529334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, effectiveness and side effects of medications used to prevent fractures.
    Reid IR
    J Intern Med; 2015 Jun; 277(6):690-706. PubMed ID: 25495429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
    Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
    J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
    Hayes KN; Brown KA; Cheung AM; Kim SA; Juurlink DN; Cadarette SM
    Ann Intern Med; 2022 Mar; 175(3):335-343. PubMed ID: 35007149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
    Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
    Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.
    Park-Wyllie LY; Mamdani MM; Juurlink DN; Hawker GA; Gunraj N; Austin PC; Whelan DB; Weiler PJ; Laupacis A
    JAMA; 2011 Feb; 305(8):783-9. PubMed ID: 21343577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials.
    Jin YZ; Lee JH; Xu B; Cho M
    BMC Musculoskelet Disord; 2019 Aug; 20(1):399. PubMed ID: 31472671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonates in the treatment of osteoporosis.
    Diab DL; Watts NB
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):487-506. PubMed ID: 22877426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration.
    Safford MM; Barasch A; Curtis JR; Outman R; Saag K
    J Clin Rheumatol; 2014 Oct; 20(7):357-62. PubMed ID: 25275761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD; Martineau P; Bryanton M; Lix LM
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between hand-grip strength and site-specific risks of major osteoporotic fracture: Results from the Japanese Population-based Osteoporosis Cohort Study.
    Kamiya K; Kajita E; Tachiki T; Ikehara S; Kouda K; Sato Y; Tamaki J; Kagamimori S; Iki M
    Maturitas; 2019 Dec; 130():13-20. PubMed ID: 31706431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.